Uruguay marijuana draws pharmaceuticals' interest: report

Foreign pharmaceutical companies have expressed interest in buying marijuana for medical uses from Uruguay, which last month became the world's first country to legalize the cultivation and sale of the drug, local media reported Monday.

The newspaper El Observador said the National Drug Board has been in contact with pharmaceutical laboratories from Israel and Chile, while Canadian businesses have contacted Uruguayan politicians and organizations to present proposals for buying cannabis.

"It is true they have consulted us to set up in Uruguay, which is a great challenge," presidential aide Diego Canepa told the newspaper.

Uruguay became the first country to legalize the cultivation, distribution and sale of marijuana December 24 when President Jose Mujica signed a law creating a government-regulated marketplace for the .

His government is currently drawing up specific rules and regulations that will apply.

The National Drug Board says it expects cannabis to go to market beginning in September.

"While it was not an objective of the law, Uruguay is becoming a biotechnology pole. It's a highly competitive area, but one that is rapidly developing," Canepa said.

"For some time, medicinal was only thought of as an analgesic, but now they are studying whether some derivatives can be used in medications," he said.

add to favorites email to friend print save as pdf

Related Stories

New York may allow medical marijuana use: report

Jan 05, 2014

New York is planning to loosen its marijuana laws to allow limited use of the drug by people suffering serious illness, the New York Times reported Saturday, citing state officials.

Recommended for you

Boxed warnings are common in novel therapeutics

12 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

14 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

15 hours ago

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments